Viewing Study NCT06547619



Ignite Creation Date: 2024-10-26 @ 3:37 PM
Last Modification Date: 2024-10-26 @ 3:37 PM
Study NCT ID: NCT06547619
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-08-07

Brief Title: Role of ET-1 Physical Activity and Sedentary Behavior in Microvascular Dysfunction Following GDM
Sponsor: None
Organization: None

Study Overview

Official Title: Role of ET-1 Physical Activity and Sedentary Behavior in Microvascular Dysfunction Following GDM
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Women with a history of gestational diabetes mellitus GDM are at a 2-fold greater risk for the development of overt cardiovascular disease CVD following the effected pregnancy While subsequent development of type II diabetes elevates this risk prior GDM is an independent risk factor for CVD morbidity particularly within the first decade postpartum GDM is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum despite the remission of insulin resistance following delivery Collectively while the association between GDM and elevated lifetime CVD risk is clear and available evidence demonstrates a link between GDM and vascular dysfunction in the decade following pregnancy the mechanisms mediating this persistent dysfunction remain unexamined

The purpose of this investigation is to examine the role of endothelin-1 a potent vasoconstrictor in aberrant microvascular function in otherwise healthy women with a history of GDM and to identify whether this mechanism is influenced by physical activity and sedentary behavior
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None